More than 10,000 drugs are suspended online, Pfizer involved in multiple blockbuster products

On December 27, the Jilin Provincial Public Resources Trading Center issued the "Notice on the Publication of Suspension of Information on Long-term Non-tradable Drugs" on its official website.
The eligibility for online procurement of some long-term non-tradable drugs will be suspended, involving November 1, 2020-2021.
Drugs listed on the platform without transactions on October 31, 2015
.
Judging from this long list of suspended online products, it includes cefuroxime sodium for injection, gefitinib tablets, amoxicillin tablets, entecavir dispersible tablets, amlodipine besylate tablets, and atorvastatin calcium.
11,924 drugs, including many large clinical varieties such as tablets, imatinib, and docetaxel injection, have been included in the suspension of online procurement qualifications
.
The document pointed out that if there is no transaction within one year to suspend listing of drugs (including suspended low-priced drugs), public medical institutions do have purchase needs, and pharmaceutical companies can apply for resumption of listing of the product according to the prescribed procedures before April 30, 2022.
Online qualifications, applications for enterprise restoration will no longer be accepted after the expiry date
.
Many major brands such as atorvastatin calcium tablets are on the list.
In addition to the familiar clinical varieties such as motherwort ointment, risperidone tablets, and Liuwei Dihuang pills, what has attracted attention is Pfizer’s cefoperazone sodium for injection, The related product regulations of many well-known brand drugs, such as torvastatin calcium tablets (Lipitor), idarubicin hydrochloride for injection, and amlodipine besylate tablets (Luohuoxi), have been traded at zero in the province for a long time
.
Taking atorvastatin calcium tablets as an example, this variety occupies a core position in the blood lipid regulator market in China, and it is expected that the total market share of TOP5 products will exceed 80% in 2021
.
Among them, atorvastatin calcium tablets and rosuvastatin calcium tablets have been in the top two for many years
.
However, the national post-harvest market is also reshuffling
.
In the centralized procurement and expansion carried out in 2019, Qilu Pharmaceutical, Xin'an Pharmaceutical, and Lepu won the bid for atorvastatin calcium, while the original manufacturer Pfizer did not win the bid
.
According to data from Menet.
com, the terminal chemical drug market of physical pharmacies in key cities in 2020 will exceed 50 billion yuan, of which atorvastatin calcium tablets top the list with 1.
06 billion yuan
.
At present, China's public medical institution terminals are the main sales channel for this product.
In the first half of 2021, sales increased by 13.
58% year-on-year, and urban physical pharmacy terminals declined slightly year-on-year
.
At present, the product is also produced by SECCO Pharmaceutical, Chia Tai Tianqing and Jialin Pharmaceutical, and the competition is also very fierce
.
Pfizer's atorvastatin calcium tablets (40mg, 7 tablets/box) were temporarily forced to retreat in Jilin Province
.
In addition, another blockbuster product of Pfizer, amlodipine besylate tablets (10mg, 10 tablets/box) is also on the list
.
According to data from Minai.
com, Pfizer’s amlodipine besylate tablets have maintained a positive growth trend in the case of national procurement failures, and accounted for nearly half of the market share in the pharmaceutical field.
China Resources Secco Pharmaceuticals, Yangzijiang Shanghai Haihai Nigeria Pharmaceuticals ranks second and third
.
However, the market is constantly adjusting its posture
.
A few days ago, the results of the centralized procurement of 45 commonly used drugs by Guangdong and other 13 provincial alliances were released.
There were 21 different specifications of amlodipine besylate tablets produced by 18 manufacturers.
The unit price of 20 5mg amlodipine besylate tablets is not higher than 0.
2 yuan/tablet
.
Among them, the price of tablets produced by Shandong Phoenix Pharmaceutical is as low as 0.
1512 yuan/tablet
.
It can be seen that the competition for amlodipine besylate tablets will be extremely fierce
.
In the list, there are pediatric multivitamin chewable tablets (10) (30 tablets/box), acetaminophen oral solution (3.
20, 1 bottle/box) from China-US Shanghai Squibb Pharmaceuticals Co.
, Ltd.
, and Lilly’s insulin lispro Injection [3ml: 300 units (pre-installed injection pen)], Teriparatide injection (20μg: 80μl, 2.
4ml/piece)
.
In November, the sixth batch of nationally organized centralized drug procurement (insulin special) completed bidding in Shanghai.
The bidding for premixed insulin analogues alone, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection (25R) Le 25 offered 18.
89 yuan per tube.
Insulin Aspart 30 injection that crossed Ganli Pharmaceutical won the lowest price in this group.
Eli Lilly's insulin lispro is in high demand, but the above-mentioned product regulations have no transaction records in Jilin.

.
A variety of tinib products were pressed to pause.
Look at this list.
Another feature is that there are more than ten thousand kinds of drugs, including many tinib products
.
Such as GSK's lapatinib tosylate tablets (0.
25g, 70 tablets/box), Chia Taiqing's imatinib mesylate capsules (0.
1g, 12 tablets/box), and dasatinib tablets ( 20mg, 60 / box), gefitinib sheet (0.
25g, 30 / box) and the like
.
Taking imatinib as an example, the competitive landscape is being reshaped
.
When the original imatinib was launched in 2001, the unit price was 400 yuan/tablet, and the patient’s annual cost was 300,000 yuan; after the “4+7” collection in 2018, Hausen Pharmaceuticals’ imatinib mesylate tablets won the bid.
The winning bid price was 623.
82 yuan/box, domestic generic drugs fell to 9.
8 yuan/piece, and the price was reduced by 98% in 18 years
.
Chia Tai Tianqing took the initiative to adjust the online limit of imatinib mesylate capsules (0.
1g*60) from 872.
19 yuan/box to 586.
39 yuan/box in Shaanxi at the beginning of the year.
Later, CSPC Ouyi also adjusted this specification Imatinib sulfonate tablets are listed online at a price of 700.
41 yuan
.
The total sales of imatinib tablets in public hospitals across the country in 2020 will be 1.
62 billion yuan, and competition is fierce
.
According to statistics, there are currently 11 companies applying for capsule dosage forms and 4 clinical trials are in progress
.
This year, Xinlitai transferred its imatinib mesylate raw material and its pharmaceutical-related rights and interests to Sinopharm Yixin, and the transfer of technology costs 27 million yuan (tax included)
.
Due to the continuous improvement of the accessibility of imatinib, resistance or intolerance of the first and second generation drugs has always been a major clinical pain point.
This year, the first third-generation BCR-ABL targeted drug-resistant CML therapeutic drug in China has caused market competition.
Changes, it is expected that many imatinib products will gradually be replaced by a new generation of drugs
.
Lapatinib tosylate tablets and gefitinib also have similar competition.
Since pirotinib went on the market, they have competed with lapatinib and trastuzumab in the domestic HER2 targeted drugs.
Is no longer the only world of original research drugs
.
Since the State Food and Drug Administration required gefitinib tablet manufacturers to conduct in-depth research on the mechanism of new adverse reactions, the drug market has also changed.
In addition to the original research company AstraZeneca, there are Qilu Pharmaceuticals and Hunan Kelun.
Companies such as Pharmaceuticals, Hengrui Pharmaceuticals, Tasly Diyi Pharmaceuticals, Chia Tai Tianqing, Yangtze River Pharmaceuticals, and Shanghai Chuang Nuo Pharmaceuticals participate in the competition, and the market structure is more complicated
.